货号 | CAS号 | 价格 |
---|---|---|
C153431-100mg | 117048-59-6 | ¥2,299.00 |
C153431-1g | 117048-59-6 | ¥11,999.00 |
C153431-250MG | 117048-59-6 | ¥4,399.00 |
C153431-25MG | 117048-59-6 | ¥739.00 |
C153431-5mg | 117048-59-6 | ¥239.00 |
敏感性 | 对光线敏感 |
溶解性 | DMSO: >10 mg/mL |
存贮条件 | 储存温度-20°C |
生化机理 | Combretastatin A4 is a vascular disrupting agent (VDA) that targets tumor vasculature to inhibit angiogenesis. It inhibits tubulin polymerization at the colchicine-binding site of beta-tubulin. It has antitumor activity by inhibiting AKT function in human gastric cells. The inhibited AKT activation causes decreased cell proliferation, cell cycle arrest, and reduced in vitro migration/invasiveness and in vivo metastatic ability. Combretastatin A4 is a natural stilbenoid phenol. |
别名 | (Z)-2-甲氧基-5-(3,4,5-三甲氧基苯乙烯基)苯酚;3'-羟基-3,4,4',5-四甲氧基-顺-芪 ;(Z)-2-Methoxy-5-(3,4,5-trimethoxystyryl)phenol;3'-Hydroxy-3,4,4',5-tetramethoxy-cis-stilbene;1-(3,4,5-Trimethoxyphenyl)-2-(3′-hydroxy-4′-methoxyphenyl) ethane 3,4,5-trimethoxy-3′-hydroxy-4′-methoxystilbene;2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol,;CA4 |